Evidence map›Paper›PMID 27620882›Full record

Trial reportBreast cancer research and treatment2016

ANG1005 for breast cancer brain metastases: correlation between

C C O'Sullivan, M Lindenberg, C Bryla, N Patronas, C J Peer, L Amiri-Kordestani, N Davarpanah, E M Gonzalez, M Burotto, P Choyke and 6 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Brain metastases: neuroimaging.Handbook of clinical neurology · 2018
    Review
  15. Review
  16. Peptides as drug delivery vehicles across biological barriers.Journal of pharmaceutical investigation · 2018
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

C C O'SullivanNational Cancer Institute, Bethesda, MD, USA. osullivan.ciara@mayo.edu.
M LindenbergNational Cancer Institute, Bethesda, MD, USA.
C BrylaNational Cancer Institute, Bethesda, MD, USA.
N PatronasNational Cancer Institute, Bethesda, MD, USA.
C J PeerNational Cancer Institute, Bethesda, MD, USA.
L Amiri-KordestaniNational Cancer Institute, Bethesda, MD, USA.
N DavarpanahNational Cancer Institute, Bethesda, MD, USA.
E M GonzalezNational Cancer Institute, Bethesda, MD, USA.
M BurottoNational Cancer Institute, Bethesda, MD, USA.
P ChoykeNational Cancer Institute, Bethesda, MD, USA.
S M SteinbergNational Cancer Institute, Bethesda, MD, USA.
D J LiewehrNational Cancer Institute, Bethesda, MD, USA.
W D FiggNational Cancer Institute, Bethesda, MD, USA.
T FojoNational Cancer Institute, Bethesda, MD, USA.
S BalasubramaniamNational Cancer Institute, Bethesda, MD, USA.
S E BatesNational Cancer Institute, Bethesda, MD, USA.

Funding

Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$14.4M
Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZ01SC006537 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 1997 to 2008
$379k
Intramural NIH HHS Z01 SC006537
6 · The paper itself

Abstract

purposeImproved therapies and imaging modalities are needed for the treatment of breast cancer brain metastases (BCBM). ANG1005 is a drug conjugate consisting of paclitaxel covalently linked to Angiopep-2, designed to cross the blood-brain barrier. We conducted a biomarker substudy to evaluate

methodsTen patients with measurable BCBM received ANG1005 at a dose of 550 mg/m

resultsThirty-two target and twenty non-target metastatic brain lesions were analyzed. The median tumor reduction by MRI after cycle 1 was -17.5 % (n = 10 patients, lower, upper quartiles: -25.5, -4.8 %) in target lesion size compared with baseline. Fifteen of twenty-nine target lesions (52 %) and 12/20 nontarget lesions (60 %) showed a ≥20 % decrease post-therapy in FLT-PET SUV change (odds ratio 0.71, 95 % CI: 0.19, 2.61). The median percentage change in SUV

conclusionsANG1005 warrants further study in BCBM. Results demonstrated a moderately strong association between MRI and

Indexed as

AdultAntineoplastic AgentsBiomarkersBiomarkers, TumorBrain NeoplasmsBreast NeoplasmsCombined Modality TherapyFemaleFluorodeoxyglucose F18HumansImmunohistochemistryIn Situ Hybridization, FluorescenceMagnetic Resonance ImagingMiddle AgedPaclitaxelPeptidesAntineoplastic AgentsBiomarkersBiomarkers, TumorFluorodeoxyglucose F18Paclitaxelpaclitaxel-Angiopep-2 conjugatePeptides18F-FLT–PETANG1005Breast cancer brain metastasesMRI brain

Identifiers

PMID27620882
PMCPMC6362453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.